On March 9, Autobio released a performance report. The company's sales revenue from January to December 2021 was CNY 3.767 billion yuan, a year-on-year increase of 26.48%. The net profit attributable to shareholders of listed companies was CNY 974 million yuan, a year-on-year increase of 30.21%, and the average net profit growth rate of the medical device service industry was 29.33%.

The company stated that the increase was mainly due to the effective prevention and control of the domestic COVID-19 epidemic in 2021. The number of outpatient visits in hospitals has recovered compared with the same period in 2020, so that the company's sales of magnetic particle chemiluminescence detection reagents have increased.

During the reporting period, the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses increased by CNY 278.1128 million, an increase of 40.99%, mainly due to the increase in the net profit attributable to shareholders of the listed company and the non-recurring government subsidies and wealth management income in 2020. This is due to the higher amount of profit and loss compared to 2021.